<div>In episode 4 of Primary Viewpoints, Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.</div>

In episode 4 of Primary Viewpoints, Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

4: Lp(a): The Next CVD Target?

<div>Primary Viewpoints from <em>Patient Care Online</em> features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.</div>

Medicine

Health & Fitness

Primary Viewpoints from Patient Care Online features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.

Primary Viewpoints from <em>Patient Care Online</em> features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.

Share 4: Lp(a): The Next CVD Target?

Sign up to save your podcasts

4: Lp(a): The Next CVD Target?

4: Lp(a): The Next CVD Target?